Review of the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with low left ventricular ejection fraction without diabetes mellitus
Review of the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with low left ventricular ejection fraction without diabetes mellitus
Evgeniy Vladimirovich Lomakin student, Medical Institute, Penza State University, Penza, Evgeniy.lomakin.01@yandex.ru, +79656340716, 0000‑0002‑1745‑5971
Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.
Проведен обзор литературных данных по заданной теме из базы Elibrary за 2020–2021 гг.
For citation:
Evgeniy Vladimirovich Lomakin, Review of the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with low left ventricular ejection fraction without diabetes mellitus. Ambulance Doctor. 2023;5.
The full version of the article is available for subscribers of the journal
Статья "Review of the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with low left ventricular ejection fraction without diabetes mellitus" Журнал "Ambulance Doctor /
Ambulance Doctor"
